Calithera Biosciences (NASDAQ:CALA) stock is rising today after its sapanisertib received a fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of certain lung cancer types.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
This includes unresectable or metastatic squamous non-small cell lung cancer (NSCLC).
Will CALA Stock Go Up?
Overall, CALA stock has a Moderate Buy consensus rating among analysts based on two unanimous Buys.
The average Calithera price target of $8 indicates a massive 129.22% potential upside for the stock. That’s after a nearly 92% slide in the share price over the past year.
Read full Disclosure